Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in BRCA1/2 mutation carriers and controls (The IMPACT Study)
Aims: Men who carry inherited mutations in the BRCA1 or BRCA2 genes are at increased risk of developing prostate cancer. A blood test measuring Prostate Specific Antigen (PSA) is currently the best method to screen for prostate cancer in the general population. However, the effectiveness of using PSA for screening in the BRCA1 and BRCA2 high-risk population is unknown. The overall study goal is to determine the usefulness of available screening methods in men at high risk and to determine new and more effective ways of screening for prostate cancer. Furthermore, we hope to gain a better understanding of the biological process of prostate cancer in BRCA1 and BRCA2 mutation carriers.
The NorthShore Center for Medical Genetics is collaborating with the Institute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust in the United Kingdom as well as other sites both nationally and internationally. The IMPACT study is one of the research initiatives of the NorthShore Center for Prostate Health.
The goal of the international study is to enroll 500 men with BRCA1 mutations, 350 men with BRCA2 mutations and an additional 850 men who have tested negative for known BRCA1 or BRCA2 familial mutations. At NorthShore University HealthSystem, we seek to enroll and study 100 participants.
Diagnosis: Men aged 40 to 69 years who have a known BRCA1 or BRCA2 mutation in their family.
Principal Investigator: Tina Selkirk, MS
IRB Approval Number: EH08-063
Sponsor: Mr. & Mrs. Jack and Judy Baker, CCRP award
Contact: Interested patients should contact Tina Selkirk at 847.570.4652
Open to Enrollment: Yes